Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews Protocol - Intervention

Advocacy interventions to reduce or eliminate violence and promote the physical and psychosocial well‐being of women who experience intimate partner abuse

This is not the most recent version

Collapse all Expand all

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effectiveness of advocacy interventions conducted within or outside of health care settings for women who are experiencing or have previously experienced intimate partner abuse.

Background

Intimate partner abuse
For the purpose of this review, intimate partner abuse (often termed domestic violence) is defined as abuse of a woman by a male or female partner who currently is, or formerly was, in an intimate relationship with the woman. Domestic violence against men is not included in the review. Intimate partner abuse perpetrated by women or men against male partners or ex‐partners also occurs. However, the majority of abuse with serious health and other consequences is that committed by men or women against their female partners (Henwood 2000). Abuse perpetrated by ex‐partners is included in the review since often the greatest risk to a woman is when she is preparing to leave or has just left her partner. It is estimated that between 65% and 75% of women killed by abusive partners are killed while leaving or after already leaving the relationship (Wilson 1993; FGTFDSV 1997). Intimate partner abuse may take various forms, including physical violence (ranging from slaps, punches, and kicks to assaults with a weapon and homicide), sexual violence (such as forced sex, or forced participation in degrading sexual acts), emotionally abusive behaviours (such as stalking, surveillance, threats of abuse, threats to remove children from the household, prohibiting a woman from seeing her family and friends, ongoing belittlement or humiliation, or intimidation), economic restrictions (such as preventing a woman from working, confiscating her earnings, restricting access to funds), and other controlling behaviours (Watts 2002). Additionally, abused disabled women may experience withholding of orthotic equipment, medications, transportation, or essential assistance with personal tasks, such as dressing or getting out of bed (Nosek 1998). Often the different forms of abuse co‐exist, but they may also present individually (Taft 2001). Partner abuse may also co‐exist with other forms of domestic violence, such as that perpetrated by other family members, but such abuse is not the focus of this review.

Prevalence of intimate partner abuse
The 1996 British Crime Survey for England and Wales found that 23% of women reported being physically assaulted by a current or former partner at some time in their lives, and these figures increased to 26% when frightening threats were included (Mirrlees‐Black 1991). More recently, the largest study in the United Kingdom among women general practice patients found that 41% had ever experienced physical or sexual violence from a partner or former partner and 17% had experienced it within the last year (Richardson 2002).

The UK experience described above is characteristic of that found in other countries. Abuse of women by their partners or ex‐partners is a worldwide phenomenon (Watts 2002). Research in the United States indicates that nearly one in three adult women experience at least one physical assault by a partner during adulthood and four million American women experience a serious assault by a partner during an average 12‐month period (APAPTFVF 1996). Fifty‐one cross‐sectional population surveys conducted in various countries on behalf of the World Health Organisation show a lifetime prevalence of between 10%‐50% and between 3%‐52% for the experience of physical violence in the previous year (WHO 2001; Heise 1999). Some examples from the WHO programme are given below (Table 1).

Open in table viewer
Table 1. Examples from the WHO programme (prevalence of abuse)

Country

Abuse over lifetime

Previous 12 mos.

Switzerland

21%

7%

Egypt

34%

Zimbabwe

17%

India

40%

14%

Cambodia

16%

Nicaragua

28%

12%

Canada

29%

3%

Disabled women may be at even greater risk of being abused. In a North American sample of women with physical disabilities, 62% reported having experienced emotional, physical, or sexual abuse (Nosek 1998).

Impact on health of women and use of services
Intimate partner abuse can have short‐term and long‐term negative health consequences for survivors, even after the abuse has ended (Campbell 2002). A World Development Report from the United Nations emphasises that such violence is a significant cause of death and disability on a world‐wide scale (SSI 1996) and the World Health Organisation highlights violence against women as a priority health issue (WHO 1998).

Physical health of abused women
Intimate partner abuse is one of the most common causes of injury in women. In the largest UK study of women general practice patients, 16% reported being punched in the face, 20% were punched on the body, arms or legs, and 13% were kicked on the floor. Of these women, 50% required medical attention for their injuries (Richardson 2002). Similar figures emerge from research conducted in hospital emergency rooms. In the USA a recent review estimated that 50% of all acute injuries and 21% of all injuries in women requiring urgent surgery were the result of partner abuse (Guth 2000).

In 1997, two women in England and Wales were killed each week by their current or former partners (HMSO 1998) a figure that represents 47% of all female homicides for that year (HMSO 1997). In Scotland, for homicides recorded over a ten‐year period (1991‐2000), 54% of the female victims aged 16‐59 were killed by their partner (SESS 2001). In the United States and Canada, 31%‐60% of murders of women during the 1990's were committed by intimate partners (Craven 1997; Crawford 1997; Brock 1999). Percentages may be even higher in less industrialised countries, but there is little global data on the murder of abused women (Gartner 1990). Suicide is also associated with intimate partner abuse in both industrialised and non‐industrialised countries, as is attempted suicide (Counts 1987). Abused women are five times more likely to attempt suicide compared with women who have not experienced such violence (Stark 1996).

Abused women experience many chronic health problems. The most consistent and largest physical health difference between abused and non‐abused women is the experience of gynaecological problems (e.g. sexually‐transmitted diseases, vaginal bleeding and infection, genital irritation, chronic pelvic pain, urinary‐tract infections) (Campbell 2002). Population based studies from the United States show that the likelihood of abused women exhibiting these symptoms are three times greater than average (McCauley 1995). Other conditions include chronic pain (e.g. headaches, back pain) and central nervous system symptoms (e.g. fainting and seizures),(Campbell 2002; DiazOlavarrieta 1999) self‐reported gastrointestinal symptoms (e.g. loss of appetite, eating disorders) and diagnosed functional gastrointestinal disorders (e.g. irritable bowel syndrome) (DiazOlavarrieta 1999; Coker 2000) and self‐reported cardiac symptoms (e.g. hypertension, chest pain) (Tollestrup 1999).

Health of abused women during pregnancy
Research evidence shows that intimate partner abuse continues when women becomes pregnant ‐ indeed, it may even escalate (Gazmararian 2000; Mezey 1997). A review by Campbell shows that prevalence rates of abuse during pregnancy are very similar in industrialised and non‐industrialised countries (Campbell 2002). Most studies in the United States show a prevalence of between 4%‐8%. This compares with 6%‐8% during the past year in the United Kingdom, 6%‐7% in Canada, at least 7% in South Africa, 11%‐21% in Sweden, and 13% in Nicaragua. The health risks for abused mothers and their unborn children can be serious. The most serious outcome is the death of the mother (Parsons 1999) or the foetus (McWilliams 1993; Jejeebhoy 1998). Intimate partner violence is also associated with low birth weight (Murphy 2001) premature birth and foetal injury (Mezey 1997).

Psychosocial health of abused women
The impact of partner violence has psychological parallels with the trauma of being taken hostage and subjected to torture (Dutton 1992; Herman 2001). The most prevalent mental health sequelae of intimate partner abuse are depression and post‐traumatic stress disorder (McCauley 1995; Ratner 1993; Golding 2002). Women living in abusive relationships are three times more likely to be diagnosed depressed or psychotic (Stark 1996) and they often have feelings of low self‐esteem and hopelessness (Kirkwood 1993). Living in a violent relationship may exacerbate a predisposition to depression; however, a woman's first exposure to abuse can also be a causal factor for subsequent depression (Campbell 1999; Silva 1997). Work in the United States shows that abused women are nearly four times as likely to suffer from post‐traumatic stress disorder compared with non‐abused women, and this can be directly related to experiencing intimate partner abuse (Golding 2002; Silva 1997). There is also evidence from the United States, Scandinavia and Papua New Guinea that increased suicidal tendencies are associated with abuse (Counts 1987; Golding 2002). Other signs of emotional distress associated with intimate partner abuse are self‐harm and para‐suicide (Stark 1996; Heath 2003) anxiety, insomnia and social dysfunction (Ratner 1993). A Nicaraguan study found that 70% of cases of emotional distress were believed to be a direct consequence of abuse (Ellsberg 1999).

In industrialised countries a further mental health problem associated with partner violence is the abuse of alcohol and drugs (McCauley 1995; Ratner 1993; Golding 2002). Women who have experienced physical or psychological violence are fifteen times more likely to abuse alcohol and nine times more likely to abuse drugs than are non‐abused women (Stark 1996). There is also evidence that alcohol and drug abuse for some women is directly attributable to intimate partner violence (Stark 1996).

The impact of intimate partner abuse on health service usage
Women experiencing intimate partner abuse present very frequently to health services and require wide‐ranging medical services (Campbell 2002; Davidson 2001). They are admitted to hospital more often than are non‐abused women and are issued more prescriptions (Koss 1991; Wisner 1999 A Canadian study set in a hospital accident and emergency department found that abused women access medical care three times more often than do non‐abused women (Ratner 1993). There is also evidence of a positive linear relationship between severity of abuse and the use of health‐care services (Koss 1991).

It is difficult to calculate the societal economic impact of intimate partner abuse but the costs are high. In a study conducted in east London, it was estimated that the public sector costs for providing services to women and children facing violence was £7.5 million (GBP). Extrapolating these figures to the whole of the Greater London area, it was estimated that the costs were around £278 million pounds per annum (Stanko 1998). In a study that compared health plans in the United States, a 92% increase in costs was associated with partner abuse, with much of this increased cost being attributable to providing mental health care provision (Wisner 1999). Thus, in addition to the very serious individual health consequences associated with abuse, there are also wider economic implications for society.

Interventions to improve the health consequences for women who are experiencing or have previously experienced domestic violence
Interventions may be primary, secondary or tertiary. In the context of domestic violence, primary interventions are concerned with preventing the onset of abuse, secondary interventions aim to prevent further abuse, and tertiary interventions deal with the consequences of abuse once the abuse has ceased. Thus it is secondary and tertiary interventions that are of relevance here.

A range of such interventions have been evaluated. Essentially these may be classified as interventions aimed at directly helping abused women (such as the provision of advocacy or therapy), and those aimed at indirectly helping abused women by improving the response of the professionals with whom they come into contact (such as the introduction of screening protocols or the provision of education and training about domestic violence). In order to have clear evidence about what professionals can do safely and effectively to decrease the impact of intimate partner abuse on women, all such interventions need to be evaluated. To this end, we are conducting a suite of systematic reviews evaluating the effectiveness of interventions to improve the health consequences for women who are experiencing or have previously experienced domestic violence.

In this review we examine the effectiveness of individual advocacy interventions. Future companion reviews will address the effectiveness of psychosocial therapeutic interventions for abused women, and screening and educational interventions aimed at the professionals who come into contact with these women.

The meaning of the term advocacy differs between countries. However, the core role of advocates is to provide information on legal, housing and financial options and to facilitate access and use of community resources such as refuges/shelters, emergency housing, and psychological services. Advocates can also provide more or less formal counselling and ongoing support. This heterogeneity in the meaning of advocacy will be explored in more depth in the review itself (based on the modes of advocacy offered in individual included studies).

The aims of advocacy are multifaceted and may include helping abused women to access services, the reduction or cessation of abuse, and the improvement of abused women's physical or psychological health. Advocacy may be offered as a stand alone service, but may also be part of a multi‐component intervention. At present, it is not known whether multi‐component interventions are more effective than those comprising a single component. There is some evidence from studies of non‐domestic violence interventions to change clinician behaviour that multi‐component interventions may be more effective than those comprising a single component, although a recent systematic review of guideline dissemination and implementation strategies showed no consistent relationship between numbers of components and effects of multifaceted interventions (Grimshaw 2004).

In this systematic review we examine the effectiveness of single and multiple‐component advocacy interventions with individual women who are still with their partners, as well as those who have already left the abusive relationship. This is because it is known that women who leave violent relationships often continue to be abused, either because the partner pursues them (Mullen 1999; Shalansky 1999) or because the woman enters another abusive relationship (Hegarty 1999; Summerfield 2003). We will include evidence from interventions initiated in any health care setting or from outside of health care if these interventions report data on health outcomes or levels of abuse, and if the findings are transferable and show what can be achieved by health care professionals. This will allow an evaluation of the evidence from various settings, thereby allowing us to ascertain if interventions initiated in healthcare or non‐healthcare settings have differential effects, an issue that is being debated currently amongst domestic violence researchers.

Objectives

To assess the effectiveness of advocacy interventions conducted within or outside of health care settings for women who are experiencing or have previously experienced intimate partner abuse.

Methods

Criteria for considering studies for this review

Types of studies

Any studies that allocate participants or clusters of participants by a random or a quasi‐random method (such as alternate allocation, allocation by birth date, etc) to an advocacy intervention compared with usual care.

Types of participants

Women aged 15 years and over (no upper age limit) identified as having experienced intimate partner abuse.

Types of interventions

Any advocacy intervention compared to usual care.

Types of outcome measures

The primary outcome measures are incidence of abuse, quality of life, depression, and anxiety. All other outcomes listed are secondary.

Primary outcomes

Incidence of abuse
(i) physical
(ii) sexual
(iii) emotional
(iv) financial
Self‐reported (such as Index of Spouse Abuse, Women's Experience of Battering, Conflict Tactics Scale) or documented in medical/police records

Psychosocial health
(i) quality of life (such as MANSA, SF‐12)
(ii) depression (such as Beck Depression Inventory, Center for Epidemiologic Studies Depression Scale)
(iii) anxiety (such as Spielberger's State‐Trait Anxiety Inventory, Beck Anxiety Inventory)

Secondary outcomes

Physical health
(i)deaths, all‐cause and partner abuse‐related (documented in medical/police records/databases)
(ii)physical injuries, such as fractures and bruises (self‐reported or documented in medical and dental records)
(iii)any chronic health disorders, such as gynaecological problems, chronic pain and gastrointestinal disorders (self‐reported or documented in medical and dental records)
(iv)any general measures of physical health (such as Daily Symptoms Questionnaire)
(v)pre‐term birth

Psychosocial health
(i)post‐traumatic stress (such as Impact of Events scale, Posttraumatic Stress Disorder Checklist)
(ii)self efficacy (such as Generalized Perceived Self‐Efficacy Scale, Sherer's Self Efficacy Scale)
(iii)self‐esteem (such as Rosenberg Self Esteem Scale, Coopersmith's Self Esteem Inventory)
(iv)perceived social support (such as Sarason's Social Support Questionnaire, Procidano & Heller's Perceived Social Support Scale)
(v)alcohol or drug abuse (such as Addiction Severity Index, Alcohol and other Drug Abuse Scale)
(vi)attempted suicide
(vii)self‐harm
(viii)impact on relationships

Socio‐economic outcome measures
(i)income
(ii)housing
(iii)participation in education
(iv)participation in work

`Proxy' or intermediate outcome measures (including take‐up of referrals to other agencies)
(i)the use of safety behaviours (e.g. use of coded telephone messages to a friend, keeping clothes at a friend's house, hiding emergency money)
(ii)the use of refuges/shelters
(iii)the use of counselling
(iv)calls to police
(v)police reports filed
(vi)protection orders sought
(vii)maintenance of family ties (i.e. children staying with mother)
We recognise that post‐intervention changes in some of these proxy measures may be associated with both `positive' and `negative' health outcomes for abused women and will require careful interpretation. For instance, increased refuge/shelter usage may reflect proactive behaviour on the behalf of abused women but it may also reflect an escalation of violence that has led to the women needing to seek safety. Where authors report any adverse outcomes from interventions, such events will be recorded and discussed in the narrative summary.

We will also document the duration of follow‐up in all included studies. At present, the optimum periods of follow‐up are not known. Thus, while an intervention may have some immediate positive effects on the health of an abused woman (such as a reduction in physical violence), other outcomes may not be so readily apparent. For example, even after leaving an abusive relationship, a woman may be traumatised for many months afterwards and any positive mental health effects may not be evident for some time. Given this uncertainty about optimum follow‐up duration, we will seek to ascertain what are the critical periods in relation to interventions in terms of health outcomes for women identified as abused. For purposes of this review, we define short‐term follow‐up as less than 12 months, medium‐term follow‐up as 12‐24 months, and long‐term follow‐up as more than two years.

Search methods for identification of studies

Searches will be made of the international literature for peer‐reviewed and non‐peer reviewed (grey literature) studies. There will be no language restrictions. A variety of sources will be used to identify studies:

A. The Cochrane Library, including the Cochrane Central Register of Controlled Trials (CENTRAL) as well as the specialist registers of the Developmental, Psychosocial and Learning Problems Collaborative Review Group and the Cochrane Oral Health Group;

B. Other electronic databases including

(i)Biomedical sciences databases
(a)Medline
(b)Embase
(c)Cinahl
(d)Lilacs
(e)Database of Abstracts of Reviews for Effectiveness (DARE)
(f)National Research Register (NRR)

(ii)Social sciences databases
(a)Social Science Citation Index (BIDS)
(b)International Bibliography of the Social Sciences
(c)PsychInfo
(iv)Criminal justice databases
(a)Legal Journals Index on Westlaw
(b)Lexis
(c)Law Direct
(d)Legal Dimensions of Human Rights
(e)Lawtel

Searches of these databases will include all studies referenced from the respective start dates of the databases. In addition to original research papers, we also will search for any relevant review articles. We will use citation tracking to identify other studies and scrutinise papers in the reference lists of included studies.

C.Other electronic sources
(i) World Health Organisation/Women's Health and Development website
(ii) Other websites related to intimate partner abuse, such as the Domestic Violence Data Source (DVDS)

D. Non‐electronic sources or unpublished research
(i)We will handsearch the following three journals for studies of interventions for domestic violence since 1980: Journal of Family Violence, Violence and Victims, Women's Health. We will also hand search the following seven journals starting from the last dates of hand searches already carried out by the Cochrane Collaboration: American Journal of Preventive Medicine, American Journal of Public Health, Annals of Emergency Medicine, Archives of Internal Medicine, Australian & New Zealand Journal of Public Health, Journal of American Medical Association, Medical Journal of Australia.
(ii)Personal communication with the first authors of all included articles
(iii) We will emai the list of primary studies included in the review to relevant researchers to check for omissions (and, in particular, omissions of non‐peer reviewed studies (grey literature)
(iv) We will consult members of intimate partner abuse groups and related organisations. Efforts will be made to make contacts in countries where English is not the first language via the WHO Domestic Violence Programme.

Searches have been developed and will include MeSH and text word terms as appropriate.
1 exp BATTERED WOMEN/
2 exp Spouse Abuse/
3 Domestic Violence/
4 (abuse$ adj3 wom#n).tw.
5 (abuse$ adj3 partner$).tw.
6 (abuse$ adj3 spouse$).tw.
7((wife or wives) adj3 batter$).tw.
8(partner$ adj3 violen$).tw
9(spous$ adj3 violen$).tw
10or/1‐9
11CONSUMER ADVOCACY/ or advocacy.mp. or PATIENT ADVOCACY/
12counseling.mp. or COUNSELING/
13mentor.mp. or MENTORS/
14or/11‐13
15intervention studies/
16evaluation studies/
17follow up studies/
18"outcome assessment (health care)"/ or "process assessment (health care)"/
19treatment outcome/
20or/15‐19
21exp WOMEN/
22Female/
23(wom#n or female$).tw.
24or/21‐23
2510 and 14 and 20 and 24

Data collection and analysis

Selection of studies
Two reviewers will independently select studies for inclusion in the review. Where possible, disagreement between the two reviewers will be resolved by discussion. If agreement cannot be reached then a third reviewer will be asked to assess whether the study fulfils the inclusion criteria. If additional information is needed to resolve the disagreement then this will be sought from the first author of the study in question.

Assessment of methodological quality
Methodological quality will be assessed independently by two reviewers. The quality of all included studies will be assessed in accord with the methodological criteria as shown in Table 1. In addition, the quality of the cluster randomised trials will be assessed in accord with criteria recommended in a recent publication (Eldridge 2004); A= high quality, B = moderate quality, C = low quality (see Table 2).

Data management and extraction
Data will be extracted independently by two reviewers and entered on paper collection forms prior to being independently entered into REVMAN. As before, where possible any disagreements between the two reviewers will be resolved by discussion. If this is not possible then a third reviewer will adjudicate and all such decisions will be documented. If necessary, the first authors of studies will be contacted to assist in resolving the disagreement.

Quality criteria for RCT designs

1. Concealment of allocation

DONE ‐ unit of allocation was institution, team or professional and any random process explicitly described, e.g. use of random number tables, OR unit of allocation was the woman or episode of care and some form of centralised randomisation scheme, an on‐site computer system or sealed opaque envelopes used

NOT CLEAR ‐ allocation procedure not described explicitly OR unit of allocation was the woman or episode of care and reported use of `list' or `table', `envelopes' or `sealed envelopes' for allocation

NOT DONE ‐ use of alternation, such as reference to case record numbers, dates of birth, day of the week or any other such approach OR unit of allocation was the woman or episode of care and reported use of any allocation process that is entirely transparent before assignment, such as an open list of random numbers or assignments OR allocation was altered by investigators, professionals or the women

2. Follow‐up of women or episodes of care

DONE ‐ outcome measures for = 70% of women randomised or women who entered the trial [Do not assume 100% follow‐up unless stated explicitly]

NOT CLEAR ‐ not specified

NOT DONE ‐ outcome measures for = 70% of women randomised or women who entered the trial

3. Blinded assessment of primary outcome(s)

DONE ‐ stated explicitly that primary outcome variables were assessed blindly OR outcome variables are objective, e.g. number of presentations to A&E for treatment of physical injuries, levels of abuse assessed by a standardised test

NOT CLEAR ‐ not specified

NOT DONE ‐ outcomes were not assessed blindly

4.4. Baseline measurement

DONE ‐ performance or women outcomes measured prior to the intervention, and no substantial differences across study groups

NOT CLEAR ‐ baseline measures not reported, or unclear whether baseline measures are different across study groups

NOT DONE ‐ differences at baseline in main outcome measures likely to undermine the post intervention differences, e.g. differences between groups before the intervention similar to those found post intervention

5. Reliable primary outcome measures

DONE ‐ two or more raters with agreement ³ 90% or kappa ³ 0.8 OR outcome assessment is objective, e.g. number of presentations to A&E for treatment of physical injuries, levels of abuse assessed by a standardised test

NOT CLEAR ‐ reliability not reported for outcome measures obtained by chart extraction or collected by an individual

NOT DONE ‐ two or more raters with agreement < 90% or kappa < 0.8

6. Protection against contamination

DONE ‐ allocation by community, institution or practice and unlikely that control group received the intervention

NOT CLEAR ‐ professionals allocated within a clinic or practice and possible that communication between experimental and control group professionals could have occurred

NOT DONE ‐ likely that control group received the intervention, e.g. cross‐over trials or if women rather than professionals were randomised

Recommended quality criteria for CRT study designs

Recommendations
1‐ Use of a clustered design is justified
2‐ Effects of clustering are allowed for in sample size calculations
3‐ Effects of clustering are allowed for in analysis
4‐ Stratification is carried out or justified if not
5‐ The number of clusters included is sufficient to enable appropriate analyses and ensure sufficient study power (at least 4 clusters per intervention group)
6‐ Analysis allows for effect of confounders or justified if not

A= HIGH QUALITY
Study complies with all 6 recommendations

B = MODERATE QUALITY
Study complies with at least recommendations 2 and 3

C = LOW QUALITY
Study complies with some of the recommendations but not recommendations 2 and 3

Data synthesis

Incomplete data
Missing data and drop‐out rates will be assessed for each of the included studies and the number of participants who are included in the final analysis will be reported as a proportion of all participants in the study. Reasons given for missing data will be provided in the narrative summary and the extent to which the results are altered by missing data will be ascertained. Best case and worst case scenario analyses will be undertaken to estimate the effect of the missing data on the results of the study. Assessment will be made of the extent to which studies have conformed to an intention‐to‐treat analysis.

Binary data
For binary outcomes (for example, `further injuries sustained' or `no further injuries sustained') a standard estimation of the odds ratio with a 95% confidence interval will be calculated.

Continuous data
Continuous data will be analysed if (i) means and standard deviations are available or are obtainable from the authors of studies, and (ii) the data are normally distributed. If the second standard is not met then such data will not be entered on the RevMan software (as this assumes a normal distribution). It will, however, be reported in the 'Other data types' of the results section where they will be analysed using appropriate non‐parametric tests.

Where all measurements are comparable and on the same scale (such as, identification rates) then these will be combined to obtain weighted mean differences. Where scales are measuring the same clinical outcomes in different ways (e.g. depression, quality of life), mean differences will be standardised in order to combine results across scales.

Investigation of heterogeneity
Consistency of results will be assessed visually and by examining I², a quantity which describes approximately the proportion of variation in point estimates that is due to heterogeneity rather than sampling error (Higgins 2002). We will supplement this with a test of homogeneity to determine the strength of evidence that the heterogeneity is genuine. Where significant statistical heterogeneity is detected differences in the characteristics of the studies or other factors will be explored as possible sources of explanation. Any differences will be summarised in a narrative synthesis.

Meta‐analysis
If there are sufficient data and it is appropriate to do so, a meta‐analysis will be performed. If there is statistical heterogeneity, a meta‐analysis will be performed using a random effects model. A fixed effect model will only be used if there is no significant statistical heterogeneity.

Sub‐group analyses
If a sufficient number of studies is identified, we will perform sub‐group analyses for the following:
‐single component interventions versus multi‐component interventions
‐interventions set in health service settings versus non‐health service settings

Sensitivity analyses
Primary analyses will be based on available data from all included studies relevant to the comparison of interest. To assess the robustness of conclusions to quality of data and approaches to analysis, sensitivity analyses will be performed. These analyses will include the following:
‐study quality
‐differential drop‐out
‐intention to treat
‐duration of follow up

Assessment of bias
Funnel plots will be drawn to investigate any relationship between effect size and study precision (closely related to sample size) (Egger 1997) Such a relationship could be due to publication or related biases or due to systematic differences between small and large studies. If a relationship is identified, clinical diversity of the studies will be further examined as a possible explanation.

Table 1. Examples from the WHO programme (prevalence of abuse)

Country

Abuse over lifetime

Previous 12 mos.

Switzerland

21%

7%

Egypt

34%

Zimbabwe

17%

India

40%

14%

Cambodia

16%

Nicaragua

28%

12%

Canada

29%

3%

Figures and Tables -
Table 1. Examples from the WHO programme (prevalence of abuse)